STOCK TITAN

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) announces a quarterly investor conference call and webcast on February 27, 2024, to report fourth-quarter and full-year financial results and provide a business update. The company focuses on immuno-dermatology innovations, with FDA-approved products and a robust pipeline for inflammatory dermatological conditions.
Positive
  • None.
Negative
  • None.
  • Quarterly investor conference call and webcast scheduled for Tuesday, February 27 at 8:30 a.m. ET

WESTLAKE VILLAGE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024. Arcutis management will host a conference call and webcast that day at 8:30 a.m. ET.

A live webcast of the call and the presentation material will be available on the “Events” section of the Company’s investor website. An archived replay of the webcast will be available on the Arcutis investor website following the conference call.

About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including two FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and X.

Forward-Looking Statements
Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 28, 2023, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contacts:

Media
Amanda Sheldon, Head of Corporate Communications
asheldon@arcutis.com

Investors
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com


FAQ

When is Arcutis Biotherapeutics, Inc. (ARQT) holding its quarterly investor conference call and webcast?

Arcutis Biotherapeutics, Inc. (ARQT) is holding its quarterly investor conference call and webcast on Tuesday, February 27, 2024, at 8:30 a.m. ET.

What is the focus of Arcutis Biotherapeutics, Inc. (ARQT)?

Arcutis Biotherapeutics, Inc. (ARQT) focuses on developing meaningful innovations in immuno-dermatology to address the needs of individuals with immune-mediated dermatological diseases and conditions.

How can investors access the live webcast of Arcutis Biotherapeutics, Inc. (ARQT) conference call?

Investors can access the live webcast of Arcutis Biotherapeutics, Inc. (ARQT) conference call on the 'Events' section of the Company’s investor website.

What does Arcutis Biotherapeutics, Inc. (ARQT) offer in its portfolio?

Arcutis Biotherapeutics, Inc. (ARQT) offers a growing portfolio including two FDA approved products targeting inflammatory dermatological conditions like scalp and body psoriasis, atopic dermatitis, and alopecia areata.

Where can more information about Arcutis Biotherapeutics, Inc. (ARQT) be found?

More information about Arcutis Biotherapeutics, Inc. (ARQT) can be found on their website www.arcutis.com or by following Arcutis on LinkedIn, Facebook, and X.

Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

ARQT Rankings

ARQT Latest News

ARQT Stock Data

1.80B
103.96M
2.15%
113.6%
21.37%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WESTLAKE VILLAGE